TRNT1 and prostate adenocarcinoma: As illustrated in Figure 1B, TRNT1 expression levels were significantly elevated in tumour tissues such as bladder urothelial carcinoma (BLCA), BC, cholangiocarcinoma (CHOL), colon adenocarcinoma (COAD), oesophageal carcinoma (ESCA), LIHC, lung adenocarcinoma (LUAD), and prostate adenocarcinoma (PRAD), as well as rectum adenocarcinoma (READ) and stomach adenocarcinoma (STAD) (all p < 0.05) compared to their respective control groups.